Use: Labeled indications
- INDICATIONS & USAGE Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
Full indications and usage US FDA label
INDICATIONS & USAGE Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4) (Patients with drug-resistant disease should be treated with regimens individualized to their situation.
Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendations of CDC. It is possible these patients may require a longer course of treatment.) It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis.
Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4
Contraindications
CONTRAINDICATIONS Pyrazinamide is contraindicated in persons: with severe hepatic damage. who have shown hypersensitivity to it. with acute gout.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE & ADMINISTRATION Pyrazinamide should always be administered with other effective antituberculous drugs. It is administered for the initial 2 months of a 6-month or longer treatment regimen for drug-susceptible patients. Patients who are known or suspected to have drug-resistant disease should be treated with regimens individualized to their situation.
Pyrazinamide frequently will be an important component of such therapy. Patients with concomitant HIV infection may require longer courses of therapy. Physicians treating such patients should be alert to any revised recommendations from CDC for this group of patients. Usual dose: Pyrazinamide is administered orally, 15 to 30 mg/kg once daily.
Older regimens employed 3 to 4 divided doses daily, but most current recommendations are for once a day. Three grams per day should not be exceeded. The CDC recommendations do not exceed 2 g per day when given as a daily regimen (see table). Alternatively, a twice weekly dosing regimen (50 to 70 mg/kg twice weekly based on lean body weight) has been developed to promote patient compliance with a regimen on an outpatient basis.
In studies evaluating the twice weekly regimen, doses of pyrazinamide in excess of 3 g twice weekly have been administered. This exceeds the recommended maximum 3 g/daily dose. However, an increased incidence of adverse reactions has not been reported. The table is taken from the CDC-American Thoracic Society joint recommendations: 4 Recommended Drugs for the Initial Treatment of Tuberculosis in Children and Adults Drug Daily Dose* Maximal Daily Dose in Children and Adults Twice Weekly Dose Children Adults Children Adults Isoniazid 10 to 20 mg/kg PO or IM 5 mg/kg PO or IM 300 mg 20 to 40 mg/kg Max. 900 mg 15 mg/kg Max. 900 mg Rifampin 10 to 20 mg/kg PO 10 mg/kg PO 600 mg 10 to 20 mg/kg Max. 600 mg 10 mg/kg Max. 600 mg Pyrazinamide 15 to 30 mg/kg PO 15 to 30 mg/kg PO 2 g 50 to 70 mg/kg 50 to 70 mg/kg Streptomycin 20 to 40 mg/kg IM 15 mg/kg** IM 1 g** 25 to 30 mg/kg IM 25 to 30 mg/kg IM Ethambutol 15 to 25 mg/kg PO 15 to 25 mg/kg PO 2.5 g 50 mg/kg 50 mg/kg Definition of abbreviations: PO = perorally; IM = intramuscularly. * Doses based on weight should be adjusted as weight changes. **In persons older than 60 yrs of age the daily dose of streptomycin should be limited to 10 mg/kg with a maximal dose of 750 mg.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
PEDIATRIC USE Pyrazinamide regimens employed in adults are probably equally effective in pediatric patients. 4, 10, 11 Pyrazinamide appears to be well tolerated in pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
GERIATRIC USE Clinical studies of pyrazinamide did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic or renal function, and of concomitant disease or other drug therapy.
It does not appear that patients with impaired renal function require a reduction in dose. It may be prudent to select doses at the low end of the dosing range, however. 13
Dosage forms
Philippines
- Suspension: 250 mg/5 mL, 500 mg per 5 mL, 500 mg/5 mL
- Tablet: 500 mg
- Oral suspension: 250 mg/5 mL, 500 mg/5 mL
Registered products in the Philippines
21 products registered with the Food and Drug Administration (FDA) Philippines list Pyrazinamide as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: yrazinamide (1 product). Products registered under these spellings are included in the table and marked.
All registered products21
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
NonePyrazinamide | 250 mg/5 mL Oral SuspensionAmber boston round bottle x 60 mL (Box of 1's); Amber boston round bottle x 120 mL (Box of 1's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-9123 | Sep 4, 2030 | |
NonePyrazinamide | 250 mg/5 mL SuspensionAmber bottle x 60 mL | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DR-XY38648 | Oct 18, 2030 | |
NonePyrazinamide | 250 mg/5 mL SuspensionBoston Round Amber Bottle x 60 mL (Box of 1's); Boston Round Amber Bottle x 120 mL (Box of 1's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5757 | Jan 17, 2028 | |
NonePyrazinamide | 250 mg/5 mL SuspensionBoston Round Amber Bottle x 120mL (Box of 1's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-5757-02 | Jan 17, 2028 | |
NonePyrazinamide | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | — | DRP-1403 | Mar 19, 2029 | |
NonePyrazinamide | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories Inc.Philippines | Firstmed Theraconcept Inc. | DRP-1403-01 | Mar 19, 2029 | |
PyracoxPyrazinamide | 500 mg TabletAlu-PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Huazhong Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-15923 | Oct 1, 2029 | |
PyragenPyrazinamide | 250 mg/5 mL SuspensionBoston Round Amber Bottle x 120 mL (Box of 1's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-16547-01 | Apr 29, 2030 | |
PyraminPyrazinamide | 250 mg/5 mL SuspensionBoston Round Amber Bottle x 60 mL and 120 mL (Box of 1's) | RxVAT-exempt | Drugmaker's Laboratories, INc.Philippines | Terramedic, Inc. | DRP-5757-01 | Jan 17, 2028 | |
Pyrazisaph-500Pyrazinamide | 500 mg/5 mL Oral SuspensionRound Amber Glass Bottle with white ROPP Aluminum Cap x 60 mL and 120 mL (Box of 1's) | RxVAT-exempt | Bueno Salud Care India Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13060 | Oct 14, 2031 | |
PyrazuerPyrazinamide | 500 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY27982 | Oct 24, 2027 | |
PyzatherPyrazinamide | 250 mg/5 mL Suspension60 mL and 120 mL Amber Bottle (Box of 1's) | RxVAT-exempt | San Marino Laboratories CorporationPhilippines | — | DRP-5771 | Jul 25, 2028 | |
RapnamidePyrazinamide | 250 mg / 5 mL SuspensionBoston Round Amber Bottle x 120 mL (Box of 1's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-16547-02 | Apr 29, 2030 | |
Saphyrazin-500Pyrazinamide | 500 mg/ 5 mL Oral SuspensionPET round amber bottle x 60 mL and 120 mL (Box of 1's) | RxVAT-exempt | Azine Healthcare Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-12267 | Jul 7, 2027 | |
UnbrandedPyrazinamide | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 28's (Box of 672's) | RxVAT-exempt | Macleods Pharmaceuticals LimitedIndia | Importer: Macleods Pharmaceuticals Philippines, Inc. | DRP-6854 | Oct 7, 2031 | |
ZcurePyrazinamide | 250 mg/5 mL SuspensionBoston Round Glass Amber Bottle x 120 mL (Box of 1's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DR-XY27677 | Jan 14, 2029 | |
Zcure FortePyrazinamide | 500 mg/ 5 mL SuspensionBoston Round Glass Amber Bottle x 120 mL (Box of 1's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DR-XY35466 | Feb 17, 2029 | |
ZinaplexPyrazinamide | 500 mg per 5 mL SuspensionAmber bottle x 120 mL | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY28007 | Jan 7, 2028 | |
250 mg/5 mL SuspensionBoston Round Amber Bottle x 120 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-16547 | Apr 29, 2030 | ||
ZynapharPyrazinamide | 250 mg/5 mL Oral SuspensionAmber Bottle x 60 mL & 120 mL (Box of 1's) | RxVAT-exempt | J.M. Tolmann Laboratories Inc.Philippines | — | DRP-2050 | Oct 29, 2030 | |
ZYNAPHARPyrazinamide | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | TGP PHARMA INC. | DRP-1403-02 | Mar 19, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Patients started on pyrazinamide should have baseline serum uric acid and liver function determinations. Those patients with preexisting liver disease or those at increased risk for drug related hepatitis (e.g., alcohol abusers) should be followed closely. Pyrazinamide should be discontinued and not be resumed if signs of hepatocellular damage or hyperuricemia accompanied by an acute gouty arthritis appear.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS General Fever, porphyria and dysuria have rarely been reported. Gout (see PRECAUTIONS). Gastrointestinal The principal adverse effect is a hepatic reaction (see WARNINGS). Hepatotoxicity appears to be dose related, and may appear at any time during therapy. GI disturbances including nausea, vomiting and anorexia have also been reported.
Hematologic and Lymphatic Thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. Adverse effects on blood clotting mechanisms have also been rarely reported. Other Mild arthralgia and myalgia have been reported frequently.
Hypersensitivity reactions including rashes, urticaria, and pruritus have been reported. Fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely.
Pregnancy considerations
Pregnancy (US label) US FDA label
PREGNANCY Teratogenic Effects – Pregnancy Category C Animal reproduction studies have not been conducted with pyrazinamide. It is also not known whether pyrazinamide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pyrazinamide should be given to a pregnant woman only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
NURSING MOTHERS Pyrazinamide has been found in small amounts in breast milk. Therefore, it is advised that pyrazinamide be used with caution in nursing mothers taking into account the risk-benefit of this therapy. 9
Pharmacokinetics
The CSF concentration is approximately equal to concurrent steady-state plasma concentrations in patients with inflamed meninges. 1 Pyrazinamide is approximately 10% bound to plasma proteins. 2 The half-life (t 1/2 ) of pyrazinamide is 9 to 10 hours in patients with normal renal and hepatic function.
The plasma half-life may be prolonged in patients with impaired renal or hepatic function.
Pyrazinoic acid is hydroxylated to the main excretory product, 5-hydroxypyrazinoic acid. 3 Approximately 70% of an oral dose is excreted in urine, mainly by glomerular filtration within 24 hours. 3 Pyrazinamide may be bacteriostatic or bactericidal against Mycobacterium tuberculosis depending on the concentration of the drug attained at the site of infection.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Pyrazinamide is well absorbed from the GI tract and attains peak plasma concentrations within 2 hours. Plasma concentrations generally range from 30 to 50 mcg/mL with doses of 20 to 25 mg/kg. It is widely distributed in body tissues and fluids including the liver, lungs and cerebrospinal fluid (CSF).
The CSF concentration is approximately equal to concurrent steady-state plasma concentrations in patients with inflamed meninges. 1 Pyrazinamide is approximately 10% bound to plasma proteins. 2 The half-life (t 1/2) of pyrazinamide is 9 to 10 hours in patients with normal renal and hepatic function. The plasma half-life may be prolonged in patients with impaired renal or hepatic function.
Pyrazinamide is hydrolyzed in the liver to its major active metabolite, pyrazinoic acid. Pyrazinoic acid is hydroxylated to the main excretory product, 5-hydroxypyrazinoic acid. 3 Approximately 70% of an oral dose is excreted in urine, mainly by glomerular filtration within 24 hours. 3 Pyrazinamide may be bacteriostatic or bactericidal against Mycobacterium tuberculosis depending on the concentration of the drug attained at the site of infection.
The mechanism of action is unknown. In vitro and in vivo the drug is active only at a slightly acidic pH.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Pyrazinamide 500 mg Tablet | ₱1.85–₱3.49Reference ₱1.85 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Pyrazinamide |
| PNF listing | Oral: 500 mg tablet |
| PNF listing | Oral: 250 mg/5 mL and 500 mg/ 5mL suspension, 120 mL |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Pyrazinamide · ANI Pharmaceuticals, Inc. [US FDA-approved label, version 2, March 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=262d8829-728c-48db-b89b-88d13b87e684
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .

